Skip to content
‹ Back to IndustriesSciences

What AI Means for Future Scientists

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly. History shows that technology does indeed change the nature of work. Perhaps the most dramatic example of this was the industrial revolution during the late 18th and…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Samuel Miller · · AiArtificial IntelligenceAutomationHuman Jobs
Share
What AI Means for Future Scientists

Key takeaways

01

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly.

02

History shows that technology does indeed change the nature of work.

03

Perhaps the most dramatic example of this was the industrial revolution during the late 18th and…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly. History shows that technology does indeed change the nature of work. Perhaps the most dramatic example of this was the industrial revolution during the late 18th and early 19th centuries that saw Europe and America transform from agrarian states to mechanized giants powered by coal and whale oil.

A New Revolution?

Today a quieter but no less drastic shift is taking place as mobile technology, blockchain, and artificial intelligence (AI), among other digital technologies, change the nature of work for many. While a first reaction might be to worry for the safety of human jobs, it is more accurate to say that technology changes the nature of certain jobs.

For example, ATMs did not remove the job of the bank teller, it simply altered their primary role from dispensing cash, to opening accounts and other clerical tasks.

The AI Effect

Perhaps the most disruptive, and ethically vague, of these new technologies is AI. One big concern related to AI is how it will affect jobs that require advanced quantitative skills, such as those in the scientific fields. Obviously, the scientific fields encompass a great deal of jobs requiring an equally diverse set of skills and qualifications. For the purposes of this article, we are discussing jobs that require higher degree such as an MS/Ph.D, or a medical qualification such as an MD.

Beginning with the assumption that these types of jobs are more at risk of artificial intelligence automation. Jobs in scientific fields are by and large more quantitative than their counterparts in the humanities or social sciences. Quantitative work is often formulaic by nature, and therefore capable of being done by highly-intelligent computers. Certain lab processes such as component testing are already being done by machines.

However, many scientific fields also require highly specific kinds of qualitative and ethical reasoning as well. This can most easily be seen in the medical fields, where a certain amount of humanity is required to diagnose and understand medical tests.

What it Means for Science

A recent article published by a career radiologist for The Scientist magazine highlights the delicate human decisions he must make every day, decisions that, at least currently, artificial intelligence is incapable of making. He demonstrates how AI is very good at identifying the fact based “what” questions, but not the judgement based “why’s.”

These are insights based on human experience and understanding that are incredibly difficult if not impossible to program. This is the human strength of the sciences and leveraging, cultivating this advantage should become a priority for educators and institutions in the near future.

Emphasizing the human side of the sciences and making it a bigger part of the field, will help prevent AI from automating science field jobs. And it is not just the sciences; Re-discovering the humanities has been a growing movement in areas such as business as well, where fields like ethical philosophy and creative design thinking have become popular to not just avoid automation, but to inject some meaning and, well, humanity into the field. At the end of the day, machines are not human and, at least for now, there are somethings that humans are just better at.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

SM
Samuel Miller
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SM
Samuel Miller

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512